Table Graph
      published meta-analysis   sensitivity analysis   studies

control in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.92 [0.72; 1.18] 0.92[0.72; 1.18]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)10%1,098NAnot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 1.20 [0.97; 1.49] 1.20[0.97; 1.49]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)10%1,074NAnot evaluable Major thrombotic events or deathdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.96 [0.74; 1.26] 0.96[0.74; 1.26]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)10%1,091NAnot evaluable Major bleedingdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV) 0.68 [0.34; 1.36] 0.68[0.34; 1.36]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 (REV)10%1,091NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-25 00:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 649,650,589,651,968 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons